Shop by goal
Popular compounds
Research resources
Recently viewed
The 2023 FDA Peptide Compounding Decision, Explained
Short answer: in 2023 the US FDA placed a group of peptides in the category it considers too risky to be prepared by compounding pharmacies for human use - a decision investigative outlet ProPublica reports was “supported by numerous documented safety concerns.” This is a ruling about compounding drugs for people . It is separate from, and does not change, the supply of clearly labelled research-use-only reagents, which are not for human consumption.
One of the most-searched peptide questions is some version of “did the FDA ban peptides?” The accurate answer is more specific than a yes or no, and the specifics matter. Drawing on ProPublica ’s reporting on peptide safety and the compounding system, here is what actually happened and why it reinforces - rather than contradicts - the research-use-only model.
Plain-English summary. Compounding pharmacies prepare customised medicines for people; their finished products are not individually FDA-approved. The FDA controls which ingredients they may use through a “bulks list.” In 2023, several peptides were kept off / removed from eligibility for that human-use compounding route on safety grounds. New-U does not compound and does not supply for human use. This page is general information, not legal or medical advice.
What compounding pharmacies are
Compounding pharmacies mix or alter components of approved drugs to create customised medications for individual patients. As ProPublica explains, the resulting compounded products are not themselves tested or approved by the FDA the way a mass-marketed drug is. To bound that risk, the agency restricts which active ingredients compounders may use - the mechanism reporters refer to as the “bulks list.” The 2023 decision was about whether certain peptides belong on that human-use list at all.
The documented safety concerns
According to the reporting, the agency’s position rested on concrete, documented risks rather than abstract caution:
Which compounds were under review
The reporting names peptides that went through recent FDA review in this context, including growth-hormone-releasing peptide-2 (GHRP-2), ibutamoren mesylate, ipamorelin, CJC-1295, AOD-9604 and melanotan II, with kisspeptin and thymosin-alpha also referenced. The presence of a compound in a regulatory review is a statement about marketing it for human use - not a claim about its value as a laboratory research reagent.
The principle underneath the decision
Former acting FDA commissioner Janet Woodcock framed the stakes broadly, telling ProPublica that allowing unstudied compounds to reach people “would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S.” That “pact” is exactly why the legal line is drawn at intended use and labelling , a theme we cover in Are Peptides Legal? and Peptides & the FDA.
Why this reinforces research-use-only
Far from undermining it, the 2023 decision is the clearest possible explanation of why credible suppliers operate strictly in the research category. “Research use only, not for human consumption” is not a marketing flourish - it is the legal and evidentiary category the material is sold in. New-U does not compound, does not prepare material for people, and provides no dosing or medical guidance. We supply sealed, independently tested reagents with a Certificate of Analysis, and buyers are responsible for lawful, research-context handling under their local rules.
Frequently Asked Questions
Did the FDA ban peptides in 2023? Not a blanket ban. Per ProPublica , a group of peptides was placed in the category considered too risky for human-use compounding, on documented safety grounds. That is separate from labelled research reagents, which are not for human use.
Why did the FDA act? Reported risks of immune reactions (up to anaphylaxis), manufacturing impurities (bacteria, heavy metals), storage sensitivity, and a lack of general-population human data.
What does it mean for research material? It underlines that the line is intended use, not the molecule. New-U supplies research-use-only reagents with a CoA, no human-use or dosing guidance. General information, not legal or medical advice.
Related Reading
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Research Compounds
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy research peptides from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io